Aztreonam/avibactam
| Combination of | |
|---|---|
| Aztreonam | Monobactam antibacterial |
| Avibactam | Beta-lactamase inhibitor |
| Clinical data | |
| Trade names | Emblaveo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625054 |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Aztreonam/avibactam, sold under the brand name Emblaveo, is a fixed-dose combination antibacterial medication used for the treatment of aerobic Gram-negative infections.[4] It is a combination of aztreonam, a monobactam antibacterial; and avibactam, a beta-lactamase inhibitor.[4] It was developed by AbbVie and Pfizer.[4][5][6]
The combination was approved for medical use in the European Union in April 2024,[4][7] in the United Kingdom in June 2024,[8] and in the United States in February 2025.[8]
- ^ "Emblaveo 1.5 g/0.5 g powder for concentrate for solution for infusion". (emc). 21 August 2024. Retrieved 11 February 2025.
- ^ "Emblaveo- aztreonam and avibactam powder, for solution". DailyMed. 7 February 2025. Retrieved 2 April 2025.
- ^ Cite error: The named reference
Emblaveo EPARwas invoked but never defined (see the help page). - ^ a b c d e "Emblaveo Product information". Union Register of medicinal products. 22 April 2024. Retrieved 22 April 2024.
- ^ Sader, Helio S; Castanheira, Mariana; Kimbrough, John H; Kantro, Valerie; Mendes, Rodrigo E (22 March 2023). "Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)". JAC-Antimicrobial Resistance. 5 (2): dlad032. doi:10.1093/jacamr/dlad032. ISSN 2632-1823. PMC 10032302. PMID 36968952.
- ^ Livermore, David M.; Mushtaq, Shazad; Vickers, Anna; Woodford, Neil (May 2023). "Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli". International Journal of Antimicrobial Agents. 61 (5): 106776. doi:10.1016/j.ijantimicag.2023.106776. PMID 36893810. S2CID 257428399.
- ^ "European Commission Approves Pfizer's Emblaveo for Patients with Multidrug-Resistant Infections and Limited Treatment Options". Pfizer (Press release). 22 April 2024. Retrieved 22 April 2024.
- ^ a b "U.S. FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options" (Press release). AbbVie. 7 February 2025. Retrieved 11 February 2025 – via PR Newswire.